Trial Profile
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Plixorafenib (Primary) ; Cobicistat
- Indications Colorectal cancer; Glioma; Malignant melanoma; Neuroendocrine tumours; Ovarian cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Novellus Biopharma; Plexxikon
- 09 Apr 2024 Results published in a Fore Biotherapeutics media release
- 09 Apr 2024 According to Fore Biotherapeutics media release, to date, plixorafenib has demonstrated encouraging efficacy and safety data from phase 1/2a study.
- 05 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.